Knowing the Ethnic Specificity of Urinary Biomarker Proteins Could Refine Diagnosis of Lupus Nephritis
By LabMedica International staff writers Posted on 13 May 2020 |

Image: High magnification micrograph of diffuse proliferative lupus nephritis (Photo courtesy of Wikimedia Commons).
A study of biomarkers in the urine of African-Americans, Caucasian, and Asian patients suffering from lupus nephritis identified distinct patterns of proteins associated with each specific ethnicity, which may be useful in diagnosing the disorder.
Lupus nephritis (LN), one of the most severe complications of systemic lupus erythematosus (SLE), is a condition where the kidneys become inflamed and eventually lose function. It is estimated that approximately 60% of all SLE patients will develop LN, and in 10 to 15% of those patients the disease will progress to end-stage renal disease (ESRD). SLE and LN are both heavily influenced by genetics, and African-Americans are three times more likely to develop SLE than Caucasians.
The current gold standard for diagnosis of renal involvement is a renal biopsy. While biopsies are highly informative, they cannot be serially repeated and come with attendant concerns, including the invasive nature of the procedure, and the possibility that the sample taken may not be representative of the entire kidney.
Early detection and prompt treatment are known to have a significant impact on morbidity and mortality in LN, but current diagnostic techniques are not optimal for early detection. Therefore, an easily measurable biomarker for LN with high predictive value is highly desirable, and this has sparked significant research interest in this direction.
In this regard, investigators at the University of Houston (Texas, USA) screened urine samples from active LN patients for 1129 proteins using an aptamer-based platform, followed by ELISA validation in two independent cohorts comprised of 127 inactive lupus, 107 active LN, 67 active non-renal lupus patients and 74 healthy controls of three different ethnicities.
A commercially available, pre-fabricated aptamer-based-targeted proteomic assay was used for the study. In this assay, streptavidin-coated beads labeled with 1129 unique aptamers were added to each urine sample to allow them to bind to their designated protein targets. After incubation, the beads were removed from the sample, the proteins attached to the aptamers were biotinylated and all aptamer–protein complexes were cleaved from the initial streptavidin beads and re-coupled to a new bead, with the biotinylated protein attaching to the bead. The aptamers were then removed from the beads and quantitated using a DNA microarray.
Results revealed that the urine proteins that best distinguished active LN from inactive disease were ALCAM (activated leukocyte cell adhesion molecule), PF-4, properdin, and VCAM-1 (vascular cell adhesion molecule) among African-Americans; sE-selectin, VCAM-1, BFL-1 and hemopexin among Caucasians; and ALCAM, VCAM-1, TFPI and PF-4 among Asians. Most of these protein markers correlated significantly with disease activity indices in the respective ethnic groups, and surpassed conventional metrics in identifying active LN, with better sensitivity, and negative/positive predictive values. Several elevated urinary molecules were also expressed within the kidneys in LN, based on single-cell RNAseq analysis.
"While patient demographics are widely known to affect SLE disease manifestations and outcomes, there are virtually no studies investigating this phenomenon in the context of disease biomarkers," said senior author Dr. Chandra Mohan, professor of biomedical engineering at the University of Houston. "Most SLE biomarker studies focus on one demographic group or all ethnic groups combined, which yield results that may not be equally predictive in all demographic groups of SLE patients. Among African American patients, the most discriminatory biomarkers that distinguished active LN from inactive disease were urine ALCAM, PF-4, properdin, and VCAM-1. The best biomarkers lend themselves to be the best therapeutic targets because they tend to be disease drivers, and that is what is happening here with ALCAM."
The lupus nephritis study was published in the May 4, 2020, online edition of the journal Nature Communications.
Related Links:
University of Houston
Lupus nephritis (LN), one of the most severe complications of systemic lupus erythematosus (SLE), is a condition where the kidneys become inflamed and eventually lose function. It is estimated that approximately 60% of all SLE patients will develop LN, and in 10 to 15% of those patients the disease will progress to end-stage renal disease (ESRD). SLE and LN are both heavily influenced by genetics, and African-Americans are three times more likely to develop SLE than Caucasians.
The current gold standard for diagnosis of renal involvement is a renal biopsy. While biopsies are highly informative, they cannot be serially repeated and come with attendant concerns, including the invasive nature of the procedure, and the possibility that the sample taken may not be representative of the entire kidney.
Early detection and prompt treatment are known to have a significant impact on morbidity and mortality in LN, but current diagnostic techniques are not optimal for early detection. Therefore, an easily measurable biomarker for LN with high predictive value is highly desirable, and this has sparked significant research interest in this direction.
In this regard, investigators at the University of Houston (Texas, USA) screened urine samples from active LN patients for 1129 proteins using an aptamer-based platform, followed by ELISA validation in two independent cohorts comprised of 127 inactive lupus, 107 active LN, 67 active non-renal lupus patients and 74 healthy controls of three different ethnicities.
A commercially available, pre-fabricated aptamer-based-targeted proteomic assay was used for the study. In this assay, streptavidin-coated beads labeled with 1129 unique aptamers were added to each urine sample to allow them to bind to their designated protein targets. After incubation, the beads were removed from the sample, the proteins attached to the aptamers were biotinylated and all aptamer–protein complexes were cleaved from the initial streptavidin beads and re-coupled to a new bead, with the biotinylated protein attaching to the bead. The aptamers were then removed from the beads and quantitated using a DNA microarray.
Results revealed that the urine proteins that best distinguished active LN from inactive disease were ALCAM (activated leukocyte cell adhesion molecule), PF-4, properdin, and VCAM-1 (vascular cell adhesion molecule) among African-Americans; sE-selectin, VCAM-1, BFL-1 and hemopexin among Caucasians; and ALCAM, VCAM-1, TFPI and PF-4 among Asians. Most of these protein markers correlated significantly with disease activity indices in the respective ethnic groups, and surpassed conventional metrics in identifying active LN, with better sensitivity, and negative/positive predictive values. Several elevated urinary molecules were also expressed within the kidneys in LN, based on single-cell RNAseq analysis.
"While patient demographics are widely known to affect SLE disease manifestations and outcomes, there are virtually no studies investigating this phenomenon in the context of disease biomarkers," said senior author Dr. Chandra Mohan, professor of biomedical engineering at the University of Houston. "Most SLE biomarker studies focus on one demographic group or all ethnic groups combined, which yield results that may not be equally predictive in all demographic groups of SLE patients. Among African American patients, the most discriminatory biomarkers that distinguished active LN from inactive disease were urine ALCAM, PF-4, properdin, and VCAM-1. The best biomarkers lend themselves to be the best therapeutic targets because they tend to be disease drivers, and that is what is happening here with ALCAM."
The lupus nephritis study was published in the May 4, 2020, online edition of the journal Nature Communications.
Related Links:
University of Houston
Latest Molecular Diagnostics News
- D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
- New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
- Chemiluminescence Immunoassays Support Diagnosis of Alzheimer’s Disease
- Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury
- Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression
- Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
- Rapid Diagnostic Test to Halt Mother-To-Child Hepatitis B Transmission
- Simple Urine Test Could Help Patients Avoid Invasive Scans for Kidney Cancer
- New Bowel Cancer Blood Test to Improve Early Detection
- Refined Test Improves Parkinson’s Disease Diagnosis
- New Method Rapidly Diagnoses CVD Risk Via Molecular Blood Screening
- Blood Test Shows Promise for Early Detection of Dementia
- CRISPR-Based Diagnostic Test Detects Pathogens in Blood Without Amplification
- Portable Blood-Based Device Detects Colon Cancer
- New DNA Test Diagnoses Bacterial Infections Faster and More Accurately
- Innovative Bio-Detection Platform Improves Early Cancer Screening and Monitoring
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read moreCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreInnovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read morePathology
view channel
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read moreIndustry
view channel
Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the... Read more